Oric Pharmaceuticals, Inc. (ORIC): Cash & Equivalents
$45.67M
As of 2025-12-31
$37.48M
As of 2026-06-30
-11.9%
3-year compound annual growth
-10.3%
5-year compound annual growth
| Period ended | Cash & Equivalents | Change YoY | Source filing |
|---|---|---|---|
| 2025-12-31 | $45.67M | -23.1% | 2026-02-23, Balance as of period end |
| 2024-12-31 | $59.41M | +154.0% | 2026-02-23, Balance as of period end |
| 2023-12-31 | $23.38M | -65.0% | 2025-02-18, Balance as of period end |
| 2022-12-31 | $66.84M | -70.4% | 2024-03-11, Balance as of period end |
| 2021-12-31 | $226.01M | +188.1% | 2023-03-16, Balance as of period end |
| 2020-12-31 | $78.45M | -12.0% | 2022-03-21, Balance as of period end |
| 2019-12-31 | $89.16M | n/a | 2022-03-21, Balance as of period end |
Cash & Equivalents at similar companies
| Company | Year ended | Cash & Equivalents | Change YoY |
|---|---|---|---|
| Oric Pharmaceuticals, Inc. (ORIC) | 2025-12-31 | $45.67M | -23.1% |
| Alumis Inc. (ALMS) | 2025-12-31 | $89.67M | -47.1% |
| Nkarta, Inc. (NKTX) | 2025-12-31 | $39.63M | +42.2% |
| Stoke Therapeutics, Inc. (STOK) | 2025-12-31 | $84.22M | -34.2% |
| Harrow, Inc. (HROW) | 2025-12-31 | $72.93M | +54.4% |
| Tango Therapeutics, Inc. (TNGX) | 2025-12-31 | $112.28M | +61.5% |
| Ironwood Pharmaceuticals Inc (IRWD) | 2025-12-31 | $215.46M | +143.3% |
| Erasca, Inc. (ERAS) | 2025-12-31 | $73.81M | +9.0% |
| MoonLake Immunotherapeutics (MLTX) | 2025-12-31 | $334.52M | +85.4% |
Compare ORIC, ALMS, NKTX, STOK side by side · Screen every company in Pharmaceutical Preparations ↗